Navigation Links
Reportlinker Adds Genzyme Corporation: PharmaVitae Profile
Date:9/23/2010

NEW YORK, Sept. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Genzyme Corporation: PharmaVitae Profile

http://www.reportlinker.com/p0138921/Genzyme-Corporation-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark Genzyme's performance against key rivals in the prescription pharmaceutical sector

See how the company's core products of Cerezyme, Fabrazyme and Myozyme/Lumizyme will continue to act as the primary sales growth drivers

Assess the impact of the recent contamination of the Allston manufacturing facility on the company's performance through 2009

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly news update 3

Company introduction 3

Company sales 4

Company financials 4

Key products and competitors 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2002-14 6

Financial performance, 2002-14 8

Genzyme: PharmaVitae forecasts at a glance 9

Strategic insight 10

Genzyme success in ultra-niche markets 10

Combination of fast revenue growth and margin improvement leads to explosive profit growth 10

With the blockbuster model under threat, Genzyme's niche market strategy looks set to hold firm 11

High-risk blockbuster model out-dated? 11

Genzyme's niche market-targeting an alternative strategy 11

Greater economies of scale as rare genetic disorders franchise expands 12

Allston facility contamination impact Genzyme's 2009 performance 12

Genzyme's spread-risk strategy 13

The renal franchise is Genzyme's first major example of therapeutic diversification 13

Further therapeutic diversification, emerging player in oncology 14

Acquisition of Bayer products adds further strength to oncology offering 14

SWOT analysis 18

Strengths 18

Weaknesses 19

Opportunities 19

Threats 20

Table of Contents 21

Table of figures 23

Chapter 3 Quarterly news update 24

Latest quarterly sales 24

Latest comment 24

Q4 2009 - Q2 2009 24

Q3 2009 24

Genzyme: FDA panel verdict presents setback to leukemia drug 24

Q1 2009 - Q2 2009 25

Latest prescription pharma product news 25

Q3 2010 25

Q2 2010 26

Q1 2010 26

Q4 2009 26

Q3 2009 27

Q2 2009 27

Q1 2009 28

Latest corporate news 29

Q2 2010 29

Q1 2010 29

Q4 2009 29

Q3 2009 29

Q2 2009 30

Q1 2009 30

Future product milestones 31

Chapter 4 Company introduction 32

Key findings 32

Background 33

Key corporate developments 34

M&A history 35

Bone Care International 35

AnorMED acquisition 36

Mozobil: the catalyst 36

Bioenvision 37

Current corporate structure 37

Biotherapeutics 37

LSDs 38

The rarity of LSDs offers a significant niche opportunity 38

Genetics/diagnostics 39

Chapter 5 Company sales 40

Key findings 40

Prescription pharmaceutical sales and growth rate analysis, 2002-14 41

Product analysis 44

Product analysis, 2002-08 46

Product analysis, 2008-14 49

Therapy area analysis 53

Geographic analysis 57

Launch/core/expiry analysis 60

Explanation of launch/core/expiry analysis 60

Launch analysis, 2008-14 61

Core analysis, 2008-14 62

Expiry analysis, 2008-14 63

Launch/core/expiry configuration, 2008-14 64

Molecule type analysis 66

Externalization analysis 70

Chapter 6 Company financials 73

Key findings 73

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 74

Operating costs and profit analysis 76

Operating costs and profit analysis, 2002-08 77

Operating cost ratio and profit margin analysis, 2002-08 78

Operating cost ratio and profit margin analysis, 2008-14 79

Operating costs and profit analysis, 2008-14 80

Chapter 7 Key products and competitors 82

Key findings 82

Overview 83

Endocrine, metabolic and genetic disorders 84

Cerezyme 84

Overview 85

Sales forecast 86

A rare disorder, but significant sales growth 86

Allston manufacturing facility contamination impacts 2009 sales 86

Threat from Shire and Protalix toward the end of the forecast period 87

Long term threat from pharmacological chaperones, Shire/Amicus's Plicera 88

Myozyme/Lumizyme 89

Overview 89

Sales forecast 90

Genzyme's key growth driver 90

Development of Lumizyme expected to provide boost to sales 91

Fabrazyme 92

Overview 92

Sales forecast 93

Comprehensive exclusivity 93

Shire suffers blow with Replagal 93

Amicus could provide competition in the long term 94

Genitourinary 95

Renagel/Renvela 95

Overview 96

Sales forecast 97

Therapeutic diversification through M&A 97

Established product 97

Strong sales force and good safety... 97

...backed by the NKF 97

Competition does exist 98

Renvela developed in order to consolidate Genzyme's position as number one 98

Label expansion into CKD patients not on dialysis 98

Hectorol 99

Overview 99

Sales forecast 100

Product gained through acquisition 100

Used as a complimentary product 100

Competition from Amgen 100

Oncology 101

Mozobil 101

Overview 101

Sales forecast 102

Innovative therapy supporting Genzyme's exploration into oncology 102

Strong clinical trial data 102

Clolar 104

Overview 104

Sales forecast 105

Acquisition of Bioenvision provided Clolar and boosted Genzyme's oncology offering 105

While approval in AML will significantly broaden Clolar's label, increased economic constraints on healthcare systems may restrict its uptake 105

Price and further competition will impede growth 105

Central nervous system 107

Campath 107

Overview 107

Sales forecast 108

Phase II data show superior efficacy compared to Rebif 108

Safety concerns 109

Future market potential 109

Chapter 8 Appendix 111

R&D pipeline 111

References 112

Datamonitor reports 112

Abbreviations 112

About Datamonitor 114

About Datamonitor Healthcare 114

Datamonitor consulting 114

Disclaimer 116

List of Tables Table 1: Genzyme - PharmaVitae forecasts at a glance 9

Table 2: Genzyme quarterly sales ($m), Q408-Q409 24

Table 3: Genzyme future product milestones, 2010-12 31

Table 4: Genzyme's acquisition history (2000-2008) 35

Table 5: Genzyme product portfolio overview ($m), 2002-08 46

Table 6: Genzyme product portfolio overview ($m), 2008-14 49

Table 7: Genzyme prescription pharmaceutical sales by therapy area ($m), 2008-14 55

Table 8: Genzyme prescription pharmaceutical sales by geographic region ($m), 2008-14 58

Table 9: Genzyme launch portfolio overview ($m), 2008-14 61

Table 10: Genzyme core portfolio overview ($m), 2008-14 62

Table 11: Genzyme expiry portfolio overview ($m), 2008-14 63

Table 12: Genzyme prescription pharmaceutical sales by molecule type ($m), 2008-14 68

Table 13: Genzyme prescription pharmaceutical sales by source ($m), 2008-14 71

Table 14: Total Genzyme sales by business unit ($m), 2002-08 74

Table 15: Genzyme operating revenue/cost analysis ($m), 2002-08 77

Table 16: Genzyme operating cost ratio analysis (% of total revenues), 2002-08 78

Table 17: Genzyme operating cost ratio analysis (% of total revenues), 2008-14 79

Table 18: Genzyme operating revenue/cost analysis ($m), 2008-14 80

Table 19: Key products overview 83

Table 20: Cerezyme: overview 85

Table 21: Cerezyme: sales forecast ($m), 2008-14 86

Table 22: Myozyme/Lumizyme: overview 89

Table 23: Myozyme/Lumizyme: sales forecast ($m), 2008-14 90

Table 24: Fabrazyme: overview 92

Table 25: Fabrazyme: sales forecast ($m), 2008-14 93

Table 26: Renagel/Renvela: overview 96

Table 27: Renagel/Renvela: sales forecast ($m), 2008-14 97

Table 28: Hectorol: overview 99

Table 29: Hectorol: sales forecast ($m), 2008-14 100

Table 30: Mozobil: overview 101

Table 31: Mozobil: sales forecast ($m), 2008-14 102

Table 32: Clolar: overview 104

Table 33: Clolar: sales forecast ($m), 2008-14 105

Table 34: Campath: overview 107

Table 35: Campath (CNS): sales forecast ($m), 2008-14 108

Table 36: Genzyme's R&D pipeline (Phase I-registration) 111

List of Figures Figure 1: The PharmaVitae Explorer 3

Figure 2: Genzyme prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 7

Figure 3: Genzyme's financial performance ($m), 2002-14 8

Figure 4: Genzyme's therapy area diversification, 2002-14 16

Figure 5: Genzyme SWOT analysis 18

Figure 6: Genzyme timeline 34

Figure 7: Current corporate structure 37

Figure 8: Genzyme prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 42

Figure 9: Key product sales ($m), 2002-14 45

Figure 10: Genzyme key sales growth drivers and resistors ($m), 2002-08 47

Figure 11: Genzyme key sales growth drivers and resistors ($m), 2008-14 50

Figure 12: Genzyme prescription pharmaceutical sales by therapy area ($m), 2002-14 54

Figure 13: Genzyme prescription pharmaceutical sales by geographic region ($m), 2002-14 57

Figure 14: Genzyme launch/core/expiry configuration ($m), 2008-14 64

Figure 15: Genzyme prescription pharmaceutical sales by molecule type ($m), 2002-14 67

Figure 16: Genzyme prescription pharmaceutical sales by source ($m), 2002-14 70

Figure 17: Genzyme operating revenue/cost analysis ($m), 2002-14 76

To order this report:Healthcare Industry: Genzyme Corporation: PharmaVitae Profile

Healthcare Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Een app die artsen over de hele ... behandelen, hun kennis kunnen delen en van elkaar kunnen ... revolutionaire MDLinking App, ontwikkeld door een internationale groep artsen ... en oncologisch chirurg dr. Gijs van Acker . ... dinsdag 24 mei officieel gepresenteerd op het Amsterdam Startup ...
(Date:5/23/2016)... PUNE, India , May 23, 2016 ... is spread across 163 pages, profiles 12 companies and ... 280 tables and figures on the industry and its ... study that is comprehensive in nature, details the current ... of the industry including definitions, classifications, applications and industry ...
(Date:5/23/2016)... ALBANY, New York , May 23, 2016 /PRNewswire/ ... new market report titled, " Exocrine Pancreatic Insufficiency Market ... Forecast 2013 - 2023 ." According to the report, ... at a CAGR of 8.3% from 2015 to 2023 ... pancreatic insufficiency (EPI) is a condition characterized by the ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... Educational opportunities, ... housing, with more advantaged communities providing richer opportunities. Recognizing the key role of ... school improvement policies; (b) school choice policies; (c) school desegregation policies; (d) wealth-focused ...
(Date:5/24/2016)... ... May 24, 2016 , ... Regenerative Medicine is being transformed by ongoing ... therapy technology, protocols and patient results as have been achieved with Okyanos Cell ... accessible standard of care for patients worldwide. , As the Medical Advisory Chairman at ...
(Date:5/24/2016)... ... 2016 , ... Backed by decades of experience, Metroloji Okulu ... the best suited solution to meet regulatory requirements. Their professional staff also performs ... Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of medical and pharmaceutical ...
(Date:5/24/2016)... Maryland (PRWEB) , ... May 24, 2016 , ... ... announced the appointment of Jonathan (Jon) Otterstatter to its board of ... is a proven leader in the development of technological innovations that lead to ...
(Date:5/24/2016)... ... ... WaterAid launched the #perioddrama campaign to mark Menstrual Hygiene Day on May 28 and ... who do not have access to a toilet, even when they’re on their periods. , ... The (sometimes hilarious) results help shine a light on the awkwardness that women face while ...
Breaking Medicine News(10 mins):